ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PROF
UTMD (62) OSUR (31) INFU (77) ANIK (53) ⌘ Pro Terminal →

Profound Medical Corp. (PROF) — RQD Stock Rating Cockpit

$6.73 +2.44% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.75

Profound Medical Corp. (PROF) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $240.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PROF Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PROF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Profound Medical Corp. (NASDAQ: PROF) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $6.73 (+2.44% 1D, market cap $240.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PROF ranks #463 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PROF compare to UTMD and OSUR in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), PROF carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 70.8%, and ROIC of -35.0%. By comparison, UTMD (Utah Medical Products Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC 26.9%, cap $216.7M) and OSUR (OraSure Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $271.7M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while UTMD leads on capital efficiency (26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PROF?
▼

Per PROF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001628808), Profound Medical Corp. generated $16.1M in revenue (+65.3% YoY), -$42.6M in net income, and -$38.4M in free cash flow against $77.5M in total assets and $4.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.75 (+0.25%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (10)SEC (14)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.2% Base Target
$9 Bull$6 Base$5 Bear
📬 FREE PROF RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PROF)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY PROF SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (35% of score)

Altman Z-Score 5.97 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
48
Grade D$7.01-15.5% Next Q
Q2 (-2Q)
45
Grade D$5.92-4.7% Next Q
Q3 (-1Q)
43
Grade D$5.64+19.3% Next Q
Current
40
Grade D-$6.73-7.4% Hist 90D α
Trajectory: D (48) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PROF Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PROF currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.20) and Max Pain ($7.07) forces dealer call-delta covering toward $9.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PROF• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PROF Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
56.430 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
5.97>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE47% OF RANGE
L: $5$6.73H: $9
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on PROF

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 70.8% gross margin and -17.93% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (70)

Altman-Z 5.97 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (32)

13/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like PROF
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PROF)

  • ✓Walkthrough of PROF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PROF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.45%📐 HORIZONTAL RANGE
2026-11-03O $5.86H $6.73L $5.86C $6.73VOL 475.5K
RES: $7.40SUP: $5.07SMA50: $6.20SMA200: $6.65
$8.71$7.83$6.94$6.06$5.18RES $7.40SUP $5.07$6.732026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PROF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PROF Butterfly Map → + Track PROF →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +65.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PROF today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PROF. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PROF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PROF)

Health Care Rank #463 of 1015 ⚔️ UTMD vs PROF Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PROF vs. UTMD, OSUR, INFU, ANIK)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Profound Medical Corp. (PROF) ranks #463 by composite RQD confidence (40/100, grade D-) and #550 by equity capitalization ($240.0M). Within this direct 5-issuer industry benchmark cohort, INFU leads on earnings valuation at 43.4x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. INFU currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with PROF at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PROF ACTIVE
Profound Medical Corp.
D- 40/100 — 70.8% -35.0% +2.44% $240.0M Benchmark Subject
UTMD
Utah Medical Products Inc.
C 62/100 — 57.1% 26.9% +3.64% $216.7M /utmd-vs-prof →
OSUR
OraSure Technologies Inc.
E 31/100 — 41.9% -35.0% -12.31% $271.7M /osur-vs-prof →
INFU
InfuSystems Holdings Inc.
B+ 77/100 43.4x 56.0% 12.8% -1.63% $280.2M /infu-vs-prof →
ANIK
Anika Therapeutics Inc.
D+ 53/100 — 56.6% -10.2% -7.35% $280.4M /anik-vs-prof →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001628808 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Profound Medical Corp. (PROF) reported GAAP revenue of $16.1M (+65.3% vs. FY2024 revenue of $9.7M , and +172.9% cumulative change since FY2023) , GAAP net income of -$42.6M, operating cash flow of -$38.2M, and free cash flow of -$38.4M (-63.7% YoY). On the balance sheet, PROF closed FY2025 with $77.5M in total assets against $4.5M in total debt (Altman Z-Score: 5.97, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $16.1M -$42.6M -$38.2M -$38.4M $77.5M $4.5M
FY2024 (FY) 2024-12-31 $9.7M -$27.8M -$23.5M -$23.5M $70.2M $2.9M
FY2023 (FY) 2023-12-31 $5.9M -$28.3M -$22.6M -$22.6M — —

3. PROF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PROF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Profound Medical Corp. (NASDAQ: PROF) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $6.73 (+2.44% 1D, market cap $240.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PROF ranks #463 in composite RQD confidence.

How does PROF compare to UTMD and OSUR in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PROF carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 70.8%, and ROIC of -35.0%. By comparison, UTMD (Utah Medical Products Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC 26.9%, cap $216.7M) and OSUR (OraSure Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $271.7M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while UTMD leads on capital efficiency (26.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PROF?

Per PROF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001628808), Profound Medical Corp. generated $16.1M in revenue (+65.3% YoY), -$42.6M in net income, and -$38.4M in free cash flow against $77.5M in total assets and $4.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PROF trading relative to its 50-day, 200-day, and 52-week technical levels?

PROF last traded at $6.73 (+2.44% on volume of 290,387 shares), positioning the stock +8.55% above its 50-day simple moving average ($6.20) and +1.20% above its 200-day simple moving average ($6.65). Across its 52-week range of $4.80 to $8.95, PROF sits at the 46.5% percentile with a 14-day RSI of 56.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($5.89 to $7.57).

Direct Sub-Reports: PROF RQD Cockpit PROF 12M Forecast PROF Earnings & Move PROF Dividends & DRIP PROF Insiders & 13F PROF Whale Options PROF Profit Sankey PROF News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

PROF — Profound Medical Corp.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Profound Medical Corp. (PROF) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $6.73 (+2.44% 1D, market capitalization $240.0M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 70.8%, operating margin of -60.0%, and free cash flow yield of -17.93%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 5.97, Piotroski F-Score of 5/9, and Debt/Equity of 0.07x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Profound Medical Corp. (PROF) is a NASDAQ-listed issuer in the Health Care sector and Medical/Dental Instruments industry. Gross margin is reported at 70.8%, per the market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Profound Medical Corp. (PROF) reported $16.1M in annual revenue (up from $9.7M in FY2024, +65.3% YoY) and -$42.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.9M revenue, -$28.3M net income) through FY2025, PROF scaled operating cash flow to -$38.2M and free cash flow to -$38.4M, backed by $77.5M in total assets against $4.5M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -17.93% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $4.80 – $8.95 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — The only sector-level context is the Health Care sector and Medical/Dental Instruments industry classification from the profile. Investors should treat any ripple analysis beyond that classification as unsupported by the provided sources.

  • Key Question #1: Can PROF sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $16.1M and free cash flow of -$38.4M, how will capital allocation balance growth reinvestment against $4.5M in total debt?
  • Key Question #3: How sensitive is PROF's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PROF Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Profound Medical Corp. (PROF) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PROF Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PROF Bull vs. Bear Conversation Board — What's Your Call at $6.73?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PROF 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PROF:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $8.02 (+22.1%)
📌 Pinned Debate

Revenue grew from $5.9M in FY 2023 to $16.1M in FY 2025 while the forensic balance sheet scored 14/20 with Debt/Equity of 0.07 and cash

Picked up a starter position in PROF in my $100K Virtual Cash book at $6.57. Revenue grew from $5.9M in FY 2023 to $16.1M in FY 2025 while the forensic balance sheet scored 14/20 with Debt/Equity of 0.07 and cash of $59.7M against debt of $4.5M.. Trading inside a $4.80–$8.95 52-week range with -17.93% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

SectorRotator 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (70.8%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $5.39 (-18.0%)
Spot @ $6.57

Operating income fell to -$41.3M in FY 2025 with FCF of -$38.4M and FCF yield of -17.93%, while ROIC is -35% and insider conviction sco

Here is the bear case nobody on the bull side wants to address on PROF: Operating income fell to -$41.3M in FY 2025 with FCF of -$38.4M and FCF yield of -17.93%, while ROIC is -35% and insider conviction scores only 3/20.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%